C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 5/023 (2006.01) A61K 38/05 (2006.01) C07K 5/02 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2274250
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme ("ICE"). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1- ("IL-1"), apoptosis-, interferon-.gamma. inducing factor- (IGIF), or interferon-.gamma.- ("IFN- .gamma.") mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting ICE activity and decreasing IGIF production and IFN-.gamma. production and methods for treating interleukin-1, apoptosis- and interferon- .gamma.- mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.
La présente invention concerne de nouvelles classes de composés agissant en inhibiteurs de l'enzyme de conversion de l'interleukine 1.beta. (ICE). Cette invention concerne également des compositions pharmaceutiques comprenant ces composés. Les composés et les compositions pharmaceutiques de l'invention conviennent particulièrement bien pour l'inhibition de l'activité ICE et par conséquent, conviennent avantageusement comme agent contrariant l'interleukine 1 (IL-1), les affections à médiation du facteur induisant l'apoptose, du facteur induisant l'interféron .gamma. (IGIF), de l'interféron .gamma. (IFN-.gamma.), y compris les affections inflammatoires, les maladies auto-immunes, les affections à dégénérescence osseuse, les affections proliférantes, les maladies infectieuses et les atteintes à dégénérescence. L'invention concerne également des procédés permettant d'inhiber l'activité de l'ICE, de diminuer la production d'IGIF et la production d'IFN-.gamma.. L'invention concerne en outre des procédés permettant, par utilisation des composés et compositions de l'invention, de traiter les affections à médiation de l'interleukine 1, de l'apoptose, et de l'interféron .gamma.. L'invention concerne enfin des procédés de d'élaboration des composés de l'invention.
Golec Julian M. C.
Lauffer David J.
Livingston David J.
Mullican Michael D.
Nyce Philip L.
Smart & Biggar
Vertex Pharmaceuticals Incorporated
LandOfFree
Inhibitors of interleukin-1.beta. converting enzyme does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of interleukin-1.beta. converting enzyme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of interleukin-1.beta. converting enzyme will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1703739